China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has obtained clinical trial approvals for two in-house developed drugs: CD80 mutant Fc fusion protein XZP-KM602 and DNA dependent protein kinase (DNA-PK) inhibitor XZP-6877. Both drugs are aimed at treating advanced solid tumors.
XZP-KM602: Enhancing T Cell Activation and Antitumor Activity
XZP-KM602 is a fusion protein composed of an engineered extracellular domain of human CD80 and the Fc domain of human IgG1. It maintains the structure of natural CD80 and has low immunogenicity. This drug enhances the activation of effector T cells by inhibiting PD-L1 and CTLA-4 while promoting the co-stimulation of CD28, resulting in stronger antitumor activity. Pre-clinical studies have shown that XZP-KM602 has significantly better antitumor efficacy than anti PD-L1, anti CTLA4 immune checkpoint drugs, and FPT155, a similar product developed by Five Prime Therapeutics, which is currently in Phase I clinical stage.
XZP-6877: A First-in-Class DNA-PK Inhibitor
XZP-6877 can block the main channels for DNA double strand breaks (DSBs) repair caused by radiotherapy and chemotherapy drugs, thereby improving the sensitivity of tumor cells to these treatments. It also disrupts the stability of the DNA telomere structure to inhibit the proliferation and growth of tumor cells. As the first DNA-PK inhibitor in China, XZP-6877 has leading research and development progress and technical advantages. Preclinical data indicate that it has good druggability.-Fineline Info & Tech
